Details of the Drug

General Information of Drug (ID: DMT1I52)

Drug Name
Cycloserine
Synonyms
D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin; Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Tuberculosis 1B10-1B14 Approved [2], [3]
Obsessive compulsive disorder 6B20 Phase 2 [1]
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 102.09
Topological Polar Surface Area (xlogp) -1.5
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [5]
Elimination
65% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 163.57559 micromolar/kg/day [7]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [4]
Chemical Identifiers
Formula
C3H6N2O2
IUPAC Name
(4R)-4-amino-1,2-oxazolidin-3-one
Canonical SMILES
C1[C@H](C(=O)NO1)N
InChI
InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
InChIKey
DYDCUQKUCUHJBH-UWTATZPHSA-N
Cross-matching ID
PubChem CID
6234
ChEBI ID
CHEBI:40009
CAS Number
68-41-7
DrugBank ID
DB00260
TTD ID
D02WFK
VARIDT ID
DR00197
ACDINA ID
D00158

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor ionotropic NMDA 1 (NMDAR1) TTLD29N NMDZ1_HUMAN Inhibitor [8]
Mycobacterium Biosynthetic alanine racemase (MycB alr) TT6TMZU ALR_MYCSM Inhibitor [8]
Mycobacterium D-alanine-D-alanine ligase A (MycB ddl) TTCS3P1 DDL_MYCTU Inhibitor [9]
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Agonist [10], [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Proton-coupled amino acid transporter 2 (SLC36A2) DTAOPTV S36A2_HUMAN Substrate [11]
Proton-coupled amino acid transporter 1 (SLC36A1) DT48WEM S36A1_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Bacterial infection
ICD Disease Classification 1A00-1C4Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proton-coupled amino acid transporter 1 (SLC36A1) DTP PAT1 3.58E-01 7.00E-02 2.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cycloserine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ethanol DMDRQZU Major Additive CNS depression effects by the combination of Cycloserine and Ethanol. Cystitis [GC00] [40]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Cycloserine and Polyethylene glycol. Irritable bowel syndrome [DD91] [41]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Cycloserine and Bupropion. Nicotine use disorder [6C4A] [42]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Cycloserine and Lindane. Pediculosis [1G00] [43]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Butylparaben E00142 7184 Antimicrobial preservative
FD&C blue no. 1 E00263 19700 Colorant
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferrosoferric oxide E00231 14789 Colorant
Sodium propionate E00445 2723816 Antimicrobial preservative
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cycloserine 250 mg capsule 250 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
2 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52.
10 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
11 Substrate specificity and functional characterisation of the H+/amino acid transporter rat PAT2 (Slc36a2). Br J Pharmacol. 2005 Jan;144(1):28-41.
12 Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13.
13 Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008 Sep 2;35(1-2):86-95.
14 PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74.
15 Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53.
16 Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9.
17 Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42.
18 Molecular dynamics studies of alanine racemase: a structural model for drug design. Biopolymers. 2003 Oct;70(2):186-200.
19 Mechanism-based inactivation of alanine racemase by 3-halovinylglycines. J Biol Chem. 1991 Nov 15;266(32):21657-65.
20 Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
21 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
22 Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
23 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
24 Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
26 Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
27 Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
28 Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
29 Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
30 Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
31 Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
32 Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
33 Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
34 The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
35 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
36 Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
37 Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
38 Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
39 Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
40 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
42 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
43 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]